Analysts Set OPKO Health, Inc. (NASDAQ:OPK) Target Price at $1.55

Shares of OPKO Health, Inc. (NASDAQ:OPK) have earned an average rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $1.55.

A number of brokerages recently issued reports on OPK. HC Wainwright reissued a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. Wall Street Zen upgraded OPKO Health from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Barrington Research lowered OPKO Health from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th.

Key Stories Impacting OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Royalty-backed financing adds capital without immediate dilution. OPKO secured $125 million against future royalties, providing liquidity while allowing it to retain long-term exposure to mazdutide-related growth in China. The financing strengthens the balance sheet, although it commits future royalty proceeds. OPK Raises $125 Million Against Royalties: What Investors Should Know
• Positive Sentiment: Improved earnings forecasts support the recent rally. Zacks Research raised its FY2026 EPS estimate to a loss of $0.22 from $0.29 and its FY2027 estimate to a loss of $0.28 from $0.30. The changes suggest analysts expect narrowing losses, consistent with OPKO’s latest results, which exceeded revenue and EPS expectations. OPK Climbs 12.4% in the Past Month: Can the Stock Rally Keep Going?
• Positive Sentiment: Analysts’ consensus price target indicates potential upside. The $1.55 consensus target is modestly above OPKO’s recent trading level, reflecting cautiously favorable expectations. OPKO Health Receives $1.55 Consensus Price Target from Analysts
• Neutral Sentiment: CTAP101 is advancing in a pediatric kidney-care study. The ongoing trial of extended-release CTAP101 could expand OPKO’s addressable market, but no efficacy or regulatory outcome has been reported, leaving the catalyst dependent on future clinical results. OPKO’s CTAP101 Pediatric Trial: A New Angle on Kidney Care Growth
• Negative Sentiment: Longer-term estimates remain mixed. While several near-term forecasts improved, Zacks lowered Q1 2028 and Q2 2028 estimates to a $0.06 loss and FY2028 to a $0.23 loss from $0.19, underscoring that profitability is not yet established. Clinical execution and continued losses remain key risks. Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health Stock Performance

OPKO Health stock opened at $1.46 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93. The firm has a market capitalization of $1.09 billion, a P/E ratio of -16.22 and a beta of 1.51. OPKO Health has a 1-year low of $0.98 and a 1-year high of $1.73. The company’s 50-day moving average is $1.38 and its 200 day moving average is $1.27.

OPKO Health (NASDAQ:OPK) last released its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.07. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%.The firm had revenue of $163.58 million for the quarter, compared to analysts’ expectations of $131.23 million. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. Research analysts forecast that OPKO Health will post -0.23 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in OPK. OP Asset Management Ltd purchased a new position in shares of OPKO Health during the first quarter worth approximately $1,257,000. First Trust Advisors LP bought a new stake in shares of OPKO Health during the first quarter valued at approximately $570,000. UBS Group AG boosted its holdings in shares of OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock valued at $6,745,000 after purchasing an additional 577,248 shares during the period. Comerica Bank boosted its holdings in shares of OPKO Health by 7.1% in the fourth quarter. Comerica Bank now owns 120,000 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 8,000 shares during the period. Finally, State of Wyoming bought a new position in OPKO Health in the first quarter worth approximately $190,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.